Hai Duong Pharmaceutical Medical Material JSC

Hai Duong Pharmaceutical Medical Material JSC has a debt-to-equity ratio of 0.6, indicating a relatively balanced capital structure with a moderate reliance on debt financing. The company's liquidity is assessed as medium, and its current ratio of 1.57 suggests it has sufficient short-term assets to cover its short-term liabilities. However, the company's free cash flow is negative at -190,964,487,550 VND, which may indicate pressure on liquidity and the need for external financing or operational improvements.

In terms of profitability, the company's return on equity (ROE) is 11.07%, which is a strong indicator of efficient use of shareholders' equity to generate profits. The return on assets (ROA) is 5.85%, suggesting that the company is effectively utilizing its assets to generate earnings. These metrics are in line with the industry's preferred metrics for evaluating pharmaceutical companies, which emphasize ROE and ROA as key performance indicators.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may expose the company to higher risks if demand in its primary market fluctuates. The lack of segmental or geographic diversification is a notable factor in its risk profile.

Looking ahead, the company's growth trajectory is expected to be influenced by its operational performance and market conditions. The company's operating income of 68,328,814,620 VND and net income of 55,703,190,200 VND indicate a profitable operation, but the capital expenditure of -268,445,432,980 VND suggests significant investment in infrastructure or expansion. The outlook for the current fiscal year is positive, with a projected increase in revenue and operating income, although the exact numeric deltas are not provided in the available data.

The company's risk assessment highlights a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt indicates potential liquidity constraints. The dilution risk is low, with no significant dilution potential reported in the basic shares outstanding. The company's risk profile is further supported by its strong equity base and manageable debt levels.

Recent events and filings do not indicate any major disruptions or strategic shifts for Hai Duong Pharmaceutical Medical Material JSC. The company's financial statements and disclosures are consistent with its historical performance, and there are no notable changes in its business model or market position. The absence of significant events in the recent filings suggests a stable operational environment.